The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
But camizestrant’s use could depend on uptake of monitoring – for now.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
Any hopes of differentiation could come down to side effects.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
